Beizotifan Domestic Purchasing Guide, Easily Find Regular Channels
Belzutifan is a HIF-2α inhibitor indicated for the treatment of renal cell carcinoma (RCC) associated with VHL (von Hipper-Lindau), central nervous system hemangioblastoma (CNS-HB), and pancreatic neuroendocrine tumors (pNET). VHL disease is a hereditary disease in which patients are prone to develop a variety of tumors, including renal cell carcinoma and hemangioblastoma. Therefore, the development of besetifan provides new treatment options for these patients.
Bestifan has a good anti-tumor effect by inhibiting the activity ofHIF-2α, thereby affecting the metabolism and proliferation of tumor cells. Clinical studies have shown that the drug has achieved significant efficacy in the treatment of VHL-related renal cell carcinoma and other indications, bringing new hope to patients.

In China, Bezutivan has been approved for marketing, but due to its short time on the market, the specific market price and medical insurance information are not yet fully transparent. Currently in the domestic market, the price of the Hong Kong version of the original drug is relatively high. The price of each box of 40mg*90 tablets may be more than 100,000 yuan, which puts a heavy financial burden on patients who use this drug.
In addition, there are also generic drugs of bezutivan available in overseas markets, especially the Laos version, which is also 40mg*90 tablets. Its price may be around 5,000 yuan, which is much cheaper than the original drug. Although generic drugs have price advantages, patients still need to pay attention to the quality and effectiveness of the drug when choosing to ensure safe treatment.
For patients who need to purchase Bestifan, it is recommended to consult and purchase through regular hospitals or pharmacies and follow the doctor's instructions. In China, patients can consult professional oncologists or endocrinologists about the use of this drug and related precautions. For more information on overseas drug prices and related information, please consult Yaode Medical Consultants.
Reference materials:https://www.welireg.com/
[ 免责声明 ] 本页面内容来自公开渠道(如FDA官网、Drugs官网、原研药厂官网等),仅供持有医疗专业资质的人员用于医学药学研究参考,不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市,不适用于中国境内销售和使用。如需治疗,请咨询正规医疗机构。本站不提供药品销售或代购服务。
.jpeg)